14 April 2026

ECO Animal Health Group plc

("ECO" or the "Company")

Appointment of Head of Business Development

Dr Andrew Winder to identify strategic growth opportunities for ECO's R&D pipeline

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces the appointment of Dr Andrew Winder as Head of Business Development, effective from 11 May 2026.

Andrew brings extensive strategic business development expertise to ECO, with a proven track record of driving profitable growth across global animal health markets. Andrew most recently served as Strategic Business Development Lead at Norbrook Laboratories Ltd (Norbrook), a global provider of veterinary pharmaceuticals. During his 14-year tenure at Norbrook, Andrew secured multiple co-development and distribution agreements, created a new global portfolio strategy that doubled the number of projects in Norbrook's pipeline, and negotiated distribution agreements with leading multi-national partners including Boehringer Ingelheim, Zoetis and Elanco.

In his new role, Andrew will be responsible for identifying and securing strategic opportunities, including in-licensing partnerships to grow the Company's R&D pipeline. His appointment comes at a pivotal time as ECO progresses the EU commercial launch of its live vaccine for poultry, ECOVAXXIN® MS, and continues to expand its position as a comprehensive solutions provider in animal health.

Andrew holds a PhD in Pharmaceutical Sciences from the University of Ulster and a BSc (Hons) in Microbiology from Queens University Belfast. He has also served as a member of the Board of Directors for Animal Health Europe.

David Hallas, Chief Executive Officer of ECO Animal Health, commented: "We are delighted to welcome Andrew to ECO. His strategic vision, proven ability to negotiate complex agreements and deep understanding of the animal health landscape make him a valuable addition to our team. As we advance our R&D pipeline and expand our commercial footprint, Andrew's expertise in portfolio management and strategic partnerships will be instrumental in driving our next phase of growth."

Dr Andrew Winder, newly appointed Head of Business Development, added: "I am excited to be joining ECO at a crucial inflection point in the Company's evolution. ECO has built an impressive foundation with Aivlosin^® and is now bringing innovative products from its proprietary R&D pipeline to market and I look forward to working with the talented team to identify growth opportunities that will strengthen ECO's position as leader in animal health."

-Ends-

Contacts

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin^® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

Click here for more information: https://ecoanimalhealth.com